Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy
Launched by FOREST LABORATORIES · Apr 30, 2008
Trial Information
Current as of August 28, 2025
Completed
Keywords
ClinConnect Summary
The study will include three phases: screening, treatment and follow-up. Screening: this phase will last a maximum of 30 days and subjects eligibility will be evaluated after informed consent signature. Endoscopy and Urea Breath test will be performed in addition to the baseline routine evaluations.
Treatment: Subjects assigned to OAC will be treated for 7 days. Those assigned to Pylera will be treated for 10 days. A randomization visit will take place on Day 0 and an end-of-treatment visit will take place between day 8 and 14.
Follow-up: includes two visits. approximately one and two mon...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Positive H. Pylori status;
- • Presence of upper gastro-intestinal symptoms;
- • Mental and legal ability to sign informed consent.
- Exclusion Criteria:
- • Previous surgery of the GI tract;
- • Clinically significant impairment of renal or hepatic function;
- • Severe unstable cardiovascular, pulmonary or endocrine disease;
- • Barrett's oesophagus or high-grade dysplasia;
- • Dysphagia or vomiting as major symptoms.
About Forest Laboratories
Forest Laboratories, a subsidiary of Allergan, is a leading global pharmaceutical company dedicated to the development and commercialization of innovative therapies that address unmet medical needs. With a strong focus on central nervous system disorders, including depression and anxiety, as well as other therapeutic areas, Forest Laboratories emphasizes rigorous clinical research and development to ensure the safety and efficacy of its products. The organization is committed to advancing healthcare through scientific excellence, collaboration, and a patient-centered approach, aiming to enhance the quality of life for individuals worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bath, , United Kingdom
Patients applied
Trial Officials
Monique Giguère, PhD
Study Director
Axcan Pharma inc
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials